WO2007031291A2 - Foodstuff additive - Google Patents
Foodstuff additive Download PDFInfo
- Publication number
- WO2007031291A2 WO2007031291A2 PCT/EP2006/008911 EP2006008911W WO2007031291A2 WO 2007031291 A2 WO2007031291 A2 WO 2007031291A2 EP 2006008911 W EP2006008911 W EP 2006008911W WO 2007031291 A2 WO2007031291 A2 WO 2007031291A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acids
- protein
- foodstuff additive
- additional food
- lycopene
- Prior art date
Links
- 239000000654 additive Substances 0.000 title abstract 4
- 230000000996 additive effect Effects 0.000 title abstract 4
- 235000001014 amino acid Nutrition 0.000 claims abstract description 24
- 150000001413 amino acids Chemical class 0.000 claims abstract description 24
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 15
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims abstract description 14
- 240000003768 Solanum lycopersicum Species 0.000 claims abstract description 14
- 235000018102 proteins Nutrition 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 235000005911 diet Nutrition 0.000 claims abstract description 10
- 230000037213 diet Effects 0.000 claims abstract description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000011630 iodine Substances 0.000 claims abstract description 9
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 6
- 239000011707 mineral Substances 0.000 claims abstract description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 5
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract description 5
- 239000011777 magnesium Substances 0.000 claims abstract description 5
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 5
- 239000011591 potassium Substances 0.000 claims abstract description 5
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 5
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 claims abstract description 4
- 229940024606 amino acid Drugs 0.000 claims description 23
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 14
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 14
- 229960004999 lycopene Drugs 0.000 claims description 14
- 235000012661 lycopene Nutrition 0.000 claims description 14
- 239000001751 lycopene Substances 0.000 claims description 14
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 5
- 235000010755 mineral Nutrition 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 229960003136 leucine Drugs 0.000 claims description 4
- 229960004452 methionine Drugs 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 229960005190 phenylalanine Drugs 0.000 claims description 4
- 229960002429 proline Drugs 0.000 claims description 4
- 239000011573 trace mineral Substances 0.000 claims description 4
- 235000013619 trace mineral Nutrition 0.000 claims description 4
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 3
- 235000019766 L-Lysine Nutrition 0.000 claims description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- 229930064664 L-arginine Natural products 0.000 claims description 3
- 235000014852 L-arginine Nutrition 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- 229930182844 L-isoleucine Natural products 0.000 claims description 3
- 239000004395 L-leucine Substances 0.000 claims description 3
- 235000019454 L-leucine Nutrition 0.000 claims description 3
- 229930195722 L-methionine Natural products 0.000 claims description 3
- 229930182821 L-proline Natural products 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 229960003767 alanine Drugs 0.000 claims description 3
- 229960005261 aspartic acid Drugs 0.000 claims description 3
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 3
- 229960002989 glutamic acid Drugs 0.000 claims description 3
- 229960002885 histidine Drugs 0.000 claims description 3
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- 229960001153 serine Drugs 0.000 claims description 3
- 229960002898 threonine Drugs 0.000 claims description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 3
- 229960004441 tyrosine Drugs 0.000 claims description 3
- 229960004295 valine Drugs 0.000 claims description 2
- 241000195493 Cryptophyta Species 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 abstract 2
- 210000003205 muscle Anatomy 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000037257 muscle growth Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000008167 Magnesium Deficiency Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 235000020855 low-carbohydrate diet Nutrition 0.000 description 2
- 235000004764 magnesium deficiency Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000191482 Cantharellus cibarius Species 0.000 description 1
- 235000015722 Cantharellus cibarius Nutrition 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000195522 Fucales Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000012888 dietary physiology Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the invention relates to a supplementary foodstuff, in particular for use in diets for sustainable obesity therapy.
- the body responds to dietary deficiencies in energy first by breaking down muscle tissue. Only then will the fat reserves of the body gradually be attacked. Responsible for this is u. a. the negative nitrogen balance. This is different if, at the same time as the diet, a balanced mix of amino acids that is immediately suitable for muscle growth is made available, and at the same time the muscle tissue is promoted through training. In this case, the administration of amino acids for the anabolic muscle tissue. At the same time an intensive fat burning takes place.
- the invention relates to a supplementary food, in particular for use in diets for sustainable obesity therapy, based on a mixture of amino acids, supplemented by
- the mass given in connection with the lycopene refers to the tomato extract in the whole, which contains lycopene.
- 20 - 25 preferably about 22 kg tomatoes are needed.
- the tomato extract is preferably in powder form.
- 1 kg of tomatoes contains about 20 mg of lycopene, whereas the content of lycopene in mature tomatoes can be significantly higher at 39-56 mg per 1 kg of tomatoes.
- More lycopene contain canned tomatoes: about 100 mg per 1 kg of tomatoes.
- the total amount of lycopene is therefore preferably between 0.05 mg and 0.2 mg, in particular 0.066 mg and 0.11 mg.
- Lycopene limits the oxidative damage caused by the increased metabolism.
- Lycopene is a radical scavenger that can neutralize radicals in the human body and thus significantly reduce the likelihood of certain cancers, such as prostate and lung cancer. Such free radicals are increasingly produced in a diet.
- lycopene is one of the most potent natural quenchers for singlet oxygen that can oxidize amino acids in proteins, nucleic acids and unsaturated fatty acids. Lycopene is a carotenoid found in tomatoes, rose hips, grapefruit, chanterelles and guavas and is rapidly absorbed by the intestine.
- the KeIp is derived from brown algae and is rich in calcium, iodine, iron, alkali and minerals. Particularly preferred is the use of Ascophyllum nodosum as brown algae from the Fucales family. Ascophyllum nodosum contains iodine u. a. a larger amount of alginates capable of binding toxic heavy metal ions in the gut and digesting them.
- the KeIp is preferably used as a fine powder with a grain size of about 250 microns.
- a typical composition in% of the dry matter is:
- iodine plays a major role in the production of thyroid hormones. It has been found that the high iodine content in the KeIp helps reduce unwanted fat. The high content of iron, which is indispensable for the oxygenation of the tissue, strengthens the organism.
- the additional food according to the invention is also well suited for the correction of malnutrition.
- Magnesium deficiency can trigger cardiac arrhythmia and convulsions in humans. Especially with low carbohydrate diet and diets and athletes there is an increased risk of magnesium deficiency.
- Phosphates are essential for all living things.
- phosphate radicals constitute constituents of DNA and RNA molecules.
- Phosphorus compounds (ATP, ADP, etc.) also play a special role in metabolism.
- Calcium phosphates are among the main components of the skeletal substances of bones and teeth.
- Magnesium and potassium may, for. B. be used in the form of magnesium oxide and potassium bicarbonate.
- the amino acid mixture used for the supplementary food according to the invention preferably contains
- amino acids used according to the invention are largely split oligopeptides. Ideally, all amino acids are monomeric. For the purposes of the invention, however, it has been found to be sufficient if the peptide bonds are largely split, d. H. Some amino acids may still be present as short-chain oligopeptides. Under short-chain oligopeptides peptides with max. 20, preferably 10 amino acids, more preferably 5 amino acids understood.
- This amino acid mixture is optimized in terms of nutritional physiology insofar as it immediately contains all essential building blocks required for the development of endogenous protein in the right proportions.
- arginine and lysine are considered growth hormone stimulants that promote fat mobilization and fat burning.
- Phenylalanine stimulates the production of the hormone cholecystokinin, which controls hunger and appetite.
- Another advantage of such an amino acid mixture is that it provides in conjunction with the added mineral salts, the iodine and the trace elements contained in KeIp for a balanced nitrogen balance.
- Glycine also has an appetizing effect.
- Leucine stimulates protein synthesis (muscle growth) and keeps blood sugar levels stable.
- Arginine has been shown to be effective against arteriosclerosis (vascular calcification).
- Methionine is involved in the production of noradrenaline and camitine, which is responsible for the transport of fatty acids through the mitochondrial membrane, where the oxidative degradation of fatty acids occurs.
- Proline is u. a. a starting material for polyamines, which are essential for cell growth and cell differentiation and develop anabolic action.
- the additional foodstuff consists for example of an amino acid mixture consisting of L-alanine 8.7 g
- the dietary supplement is fat free, carbohydrate free, purine free and cholesterol free. It is taken as part of a formula diet as a substitute or as a supplement to meals. The dosage is ever according to body weight of the patient between 40 g per day and 80 g per day. The therapy should be accompanied by qualified dieticians and / or medically.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Zusatznahrunαsmittel Zusatznahrunαsmittel
Die Erfindung betrifft ein Zusatznahrungsmittel, insbesondere für die Verwendung bei Diäten zur nachhaltigen Adipositastherapie.The invention relates to a supplementary foodstuff, in particular for use in diets for sustainable obesity therapy.
Aus der Sportmedizin ist es bekannt, dass die Einnahme von Aminosäuren in Kombination mit einer kalorienreduzierenden Ernährungsweise und Sport zur Gewichtsreduzierung führen, und zwar ohne den Abbau von Muskelgewebe, wenn zugleich intensiv trainiert wird.It is known from sports medicine that the intake of amino acids in combination with a calorie-reducing diet and exercise lead to weight reduction, without the reduction of muscle tissue, if at the same time intensively trained.
Normalerweise reagiert der Körper auf durch Diäten bewirkten Energiemangel zunächst mit Abbau von Muskelgewebe. Erst danach werden nach und nach auch die Fettreserven des Körpers in Angriff genommen. Verantwortlich hierfür ist u. a. die negative Stickstoffbilanz. Das ist anders, wenn zugleich mit der Diät eine ausgewogene und sofort für den Muskelaufbau geeignete Mischung an Aminosäuren zur Verfügung gestellt wird und gleichzeitig das Muskelgewebe durch Training gefördert wird. In diesem Fall wirkt die Gabe an Aminosäuren für das Muskelgewebe anabol. Zugleich findet eine intensive Fettverbrennung statt.Normally, the body responds to dietary deficiencies in energy first by breaking down muscle tissue. Only then will the fat reserves of the body gradually be attacked. Responsible for this is u. a. the negative nitrogen balance. This is different if, at the same time as the diet, a balanced mix of amino acids that is immediately suitable for muscle growth is made available, and at the same time the muscle tissue is promoted through training. In this case, the administration of amino acids for the anabolic muscle tissue. At the same time an intensive fat burning takes place.
Dieser wünschenswerte Effekt wird allerdings erheblich reduziert, wenn das be- gleitende Training weniger intensiv ist.However, this desirable effect is significantly reduced if the accompanying training is less intense.
Es ist deshalb Aufgabe der Erfindung, ein für die nachhaltige Adipositastherapie geeignetes, Diät begleitendes Zusatznahrungsmittel bereit zu stellen, welches den Muskelaufbau bei gleichzeitiger Fettverbrennung fördert, ohne auf übermäßiges körperliches Training angewiesen zu sein. Gegenstand der Erfindung ist ein Zusatznahrungsmittel, insbesondere für die Verwendung bei Diäten zur nachhaltigen Adipositastherapie, auf der Basis einer Mischung von Aminosäuren, ergänzt durchIt is therefore an object of the invention to provide a suitable for sustainable obesity therapy, diet accompanying supplementary food, which promotes muscle growth with simultaneous fat burning, without having to rely on excessive exercise. The invention relates to a supplementary food, in particular for use in diets for sustainable obesity therapy, based on a mixture of amino acids, supplemented by
Mineralsalze, enthaltend 0,5 g bis 0,7 g Calciumphosphat, 0,3 g bis 0,4 g Magnesium und 0,15 g bis 0,25 g Kalium,Mineral salts containing 0.5 g to 0.7 g of calcium phosphate, 0.3 g to 0.4 g of magnesium and 0.15 g to 0.25 g of potassium,
0,04 g bis 0,06 g KeIp, enthaltend 7 mg bis 8 mg Jod und Spurenelemente, und0.04 g to 0.06 g KeIp containing 7 mg to 8 mg iodine and trace elements, and
0,15 g bis 0,25 g Lycopin in Form von Tomatenextrakt.0.15 g to 0.25 g lycopene in the form of tomato extract.
(Sämtliche Gewichtsangaben bezogen auf 100 g Protein).(All weights are based on 100 g of protein).
Die im Zusammenhang mit dem Lycopin angegebene Masse bezieht sich auf den Tomatenextrakt im Ganzen, der lycopinhaltig ist. Um 1 kg Tomatenextrakt zu erhalten, werden 20 - 25, vorzugsweise ca. 22 kg Tomaten benötigt. Der Tomatenextrakt liegt vorzugsweise pulverförmig vor. 1 kg Tomaten enthält ca. 20 mg Lycopin, wobei der Gehalt an Lycopin bei reifen Tomaten deutlich höher bei 39 - 56 mg pro 1 kg Tomaten liegen kann. Noch mehr Lycopin enthalten Dosentomaten: ca. 100 mg pro 1 kg Tomaten. Die Gesamtmenge an Lycopin beträgt demnach vorzugsweise zwischen 0,05 mg und 0,2 mg, insbesondere 0,066 mg und 0,11 mg.The mass given in connection with the lycopene refers to the tomato extract in the whole, which contains lycopene. To obtain 1 kg of tomato extract, 20 - 25, preferably about 22 kg tomatoes are needed. The tomato extract is preferably in powder form. 1 kg of tomatoes contains about 20 mg of lycopene, whereas the content of lycopene in mature tomatoes can be significantly higher at 39-56 mg per 1 kg of tomatoes. More lycopene contain canned tomatoes: about 100 mg per 1 kg of tomatoes. The total amount of lycopene is therefore preferably between 0.05 mg and 0.2 mg, in particular 0.066 mg and 0.11 mg.
Grundsätzlich ist es selbstverständlich auch möglich, Lycopin in entsprechender Menge zuzusetzen, das aus anderen Quellen gewonnen wurde.In principle, it is of course also possible to add lycopene in an appropriate amount, which was obtained from other sources.
Es hat sich überraschenderweise herausgestellt, dass durch die Zugabe der angegebenen Mineralsalze und der im KeIp enthaltenen Substanzen (Jod und Spurenelemente) in Verbindung mit einer ausgewogenen, ernähungs- physiologisch optimierten Aminosäuremischung der Stoffwechsel des Körpers außerordentlich intensiv angeregt wird, wodurch die sonst nur durch körperliches Training bewirkte Anregung zum Muskelaufbau zu einem großen Teil substituiert wird. Es kommt also auch ohne intensives Training zum Aufbau von Muskelgewebe und zum Abbau von Fettgewebe. Völlig ersetzen lässt sich allerdings das Training nicht. Es kann aber auf ein für den jeweiligen Patienten angemessenes Maß reduziert werden.It has surprisingly been found that by adding the indicated mineral salts and the substances contained in KeIp (iodine and trace elements) in conjunction with a balanced, nutritionally physiologically optimized amino acid mixture, the metabolism of the body is stimulated extremely intense, which otherwise only by physical Training induced stimulation to build muscle is substituted to a large extent. It comes so even without intensive training to build of muscle tissue and breakdown of adipose tissue. However, the training can not be completely replaced. However, it can be reduced to an appropriate level for the respective patient.
Durch die Zugabe des Antioxidativmittels Lycopin werden die von dem verstärkten Stoffwechsel ausgehenden oxidativen Schäden begrenzt. Lycopin ist ein Radikalfänger, der Radikale im menschlichen Körper unschädlich machen und auf diese Weise die Wahrscheinlichkeit für bestimmte Krebsarten, beispielsweise Prostata- und Lungenkrebs, signifikant reduzieren kann. Derartige freie Radikale entstehen bei einer Diät vermehrt. Insbesondere gehört Lycopin zu den wirksamsten natürlichen Quenchern für Singulettsauerstoff, der Aminosäuren in Proteinen, Nukleinsäuren und ungesättigte Fettsäuren oxidieren kann. Lycopin ist ein Carotinoid, das insbesondere in Tomaten, Hagebutten, Grapefruits, Pfifferlingen und Guaven vorkommt und vom Darm schnell resorbiert wird.The addition of the antioxidant lycopene limits the oxidative damage caused by the increased metabolism. Lycopene is a radical scavenger that can neutralize radicals in the human body and thus significantly reduce the likelihood of certain cancers, such as prostate and lung cancer. Such free radicals are increasingly produced in a diet. In particular, lycopene is one of the most potent natural quenchers for singlet oxygen that can oxidize amino acids in proteins, nucleic acids and unsaturated fatty acids. Lycopene is a carotenoid found in tomatoes, rose hips, grapefruit, chanterelles and guavas and is rapidly absorbed by the intestine.
Der KeIp wird aus Braunalgen gewonnen und ist reich an Calcium, Jod, Eisen, Alkali und Mineralien. Besonders bevorzugt ist die Verwendung von Ascophyllum nodosum als Braunalge aus der Fucales-Familie. Ascophyllum nodosum enthält neben Jod u. a. eine größere Menge Alginate, die in der Lage sind, giftige Schwermetallionen im Darminhalt zu binden und für deren Ausscheidung mit der Verdauung zu sorgen. Der KeIp wird bevorzugt als feines Pulver mit einer Körnung von ca. 250 μm eingesetzt. Eine typische Zusammensetzung in % der Trockenmasse ist:The KeIp is derived from brown algae and is rich in calcium, iodine, iron, alkali and minerals. Particularly preferred is the use of Ascophyllum nodosum as brown algae from the Fucales family. Ascophyllum nodosum contains iodine u. a. a larger amount of alginates capable of binding toxic heavy metal ions in the gut and digesting them. The KeIp is preferably used as a fine powder with a grain size of about 250 microns. A typical composition in% of the dry matter is:
Jod spielt im Organismus hauptsächlich eine Rolle für die Produktion von Schilddrüsenhormonen. Es hat sich herausgestellt, dass der hohe Jodgehalt im KeIp beim Abbau von unerwünschtem Fett hilft. Der hohe Gehalt an Eisen, das für die Sauerstoffversorgung des Gewebes unabdingbar ist, stärkt den Organismus.In the organism, iodine plays a major role in the production of thyroid hormones. It has been found that the high iodine content in the KeIp helps reduce unwanted fat. The high content of iron, which is indispensable for the oxygenation of the tissue, strengthens the organism.
Das erfindungsgemäße Zusatznahrungsmittel ist auch gut zur Korrektur von Fehlernährungen geeignet. Magnesiummangel kann beim Menschen Herzrhythmusstörungen und Krämpfe auslösen. Gerade bei kohlenhydratarmer Ernährung und Diäten sowie bei Sportlern besteht eine erhöhte Gefahr von Magnesiummangel.The additional food according to the invention is also well suited for the correction of malnutrition. Magnesium deficiency can trigger cardiac arrhythmia and convulsions in humans. Especially with low carbohydrate diet and diets and athletes there is an increased risk of magnesium deficiency.
Phosphate sind für sämtliche Lebewesen essentiell. Insbesondere stellen Phosphatreste Bestandteile der DNA- und RNA-Moleküle dar. Auch im Stoffwechsel spielen Phosphorverbindungen (ATP, ADP, etc.) eine besondere Rolle. Calciumphosphate gehören zu den Hauptbestandteilen der Gerüstsubstanzen von Knochen und Zähnen.Phosphates are essential for all living things. In particular, phosphate radicals constitute constituents of DNA and RNA molecules. Phosphorus compounds (ATP, ADP, etc.) also play a special role in metabolism. Calcium phosphates are among the main components of the skeletal substances of bones and teeth.
Magnesium und Kalium können z. B. in Form von Magnesiumoxid und Kaliumhydrogencarbonat eingesetzt werden.Magnesium and potassium may, for. B. be used in the form of magnesium oxide and potassium bicarbonate.
Das für das Zusatznahrungsmittel gemäß der Erfindung verwendete Aminosäurengemisch enthält vorzugsweiseThe amino acid mixture used for the supplementary food according to the invention preferably contains
L-Alanin 8,7 g +/- 10 %L-Alanine 8.7 g +/- 10%
L-Arginin 8,15 g +/- 10 % L-Asparaginsäure 6 g +/- 10 %L-arginine 8,15 g +/- 10% L-aspartic acid 6 g +/- 10%
L-Glutaminsäure 11 ,1 g +/- 10 %L-glutamic acid 11, 1 g +/- 10%
L-Glycin 20,6 g +/- 10 %L-Glycine 20.6 g +/- 10%
L-Histidin 0,6 g +/- 10 %L-histidine 0.6 g +/- 10%
L-Hydroxylysin 1 g +/- 10 % L-Hydroxyprolin 11 ,4 g +/- 10 % L-Isoleucin 1 ,6 g +/- 10 %L-hydroxylysine 1 g +/- 10% L-hydroxyproline 11, 4 g +/- 10% L-isoleucine 1, 6 g +/- 10%
L-Leucin 3,3 g +/- 10 %L-leucine 3.3 g +/- 10%
L-Lysin 3,9 g +/- 10 %L-lysine 3.9 g +/- 10%
L-Methionin 0,6 g +/- 10 % L-Phenylalanin 2,1 g +/- 10 %L-methionine 0.6 g +/- 10% L-phenylalanine 2.1 g +/- 10%
L-Prolin 13,3 g +/- 10 %L-proline 13.3 g +/- 10%
L-Serin 3,1 g +/- 10 %L-serine 3.1 g +/- 10%
L-Threonin 1 ,8 g +/- 10 %L-threonine 1, 8 g +/- 10%
L-Tyrosin 0,35 g +/- 10 % L-VaNn 2,4 g +/- 10 %L-Tyrosine 0,35 g +/- 10% L-VaNn 2,4 g +/- 10%
(Alle Gewichtsangaben bezogen auf 100 g Protein).(All weights based on 100 g of protein).
Bei den erfindungsgemäß verwendeten Aminosäuren handelt es sich um weitgehend aufgespaltene Oligopeptide. Idealerweise liegen sämtliche Aminosäuren monomer vor. Für die Zwecke der Erfindung hat es sich jedoch als ausreichend herausgestellt, wenn die Peptidbindungen weitgehend aufgespalten sind, d. h. einige Aminosäuren können noch als kurzkettige Oligopeptide vorliegen. Dabei werden unter kurzkettigen Oligopeptiden Peptide mit max. 20, vorzugsweise 10 Aminosäuren, besonders bevorzugt 5 Aminosäuren verstanden.The amino acids used according to the invention are largely split oligopeptides. Ideally, all amino acids are monomeric. For the purposes of the invention, however, it has been found to be sufficient if the peptide bonds are largely split, d. H. Some amino acids may still be present as short-chain oligopeptides. Under short-chain oligopeptides peptides with max. 20, preferably 10 amino acids, more preferably 5 amino acids understood.
Die Verwendung von einzelnen Aminosäuren anstelle langkettiger Proteine hat den Vorteil, dass der Körper die Aminosäuren unmittelbar aufnehmen kann, ohne die Peptidbindungen der Proteine zunächst spalten zu müssen. Die Resorptionsrate wird damit deutlich erhöht. Bei der Verwendung von Proteinen hingegen wird ein erheblicher Teil vom Körper nicht aufgenommen und letztlich wieder ausgeschieden. Die Verabreichung von monomeren Aminosäuren oder sehr kurzkettigen Oligopeptiden ist daher erheblich effizienter. Die Gewichtsangabe „bezogen auf 100 g Protein" ist dabei so zu verstehen, dass als Protein die Gesamtmenge an Aminosäuren anzusehen ist.The use of individual amino acids instead of long-chain proteins has the advantage that the body can absorb the amino acids directly without first having to cleave the peptide bonds of the proteins. The absorption rate is thus significantly increased. When using proteins, however, a significant part of the body is not absorbed and ultimately excreted. The administration of monomeric amino acids or very short chain oligopeptides is therefore considerably more efficient. The Weight indication "based on 100 g protein" is to be understood that the total amount of amino acids is to be regarded as protein.
Diese Aminosäuremischung ist insofern ernährungsphysiologisch optimiert, als sie sofort alle wesentlichen, für den Aufbau von körpereigenem Eiweiß erforderlichen Bausteine im richtigen Mengenverhältnis bereithält. Außerdem gelten Arginin und Lysin als Stimulanzien des Wachstumshormons, welches die Fettmobilisierung und die Fettverbrennung fördert. Phenylalanin stimuliert die Produktion des Hormons Cholecystokinin, welches den Hunger und Appetit steuert. Ein weiterer Vorteil einer solchen Aminosäuremischung besteht darin, dass sie im Zusammenwirken mit den zugesetzten Mineralsalzen, dem Jod und den im KeIp enthaltenen Spurenelementen für eine ausgeglichene Stickstoffbilanz sorgt.This amino acid mixture is optimized in terms of nutritional physiology insofar as it immediately contains all essential building blocks required for the development of endogenous protein in the right proportions. In addition, arginine and lysine are considered growth hormone stimulants that promote fat mobilization and fat burning. Phenylalanine stimulates the production of the hormone cholecystokinin, which controls hunger and appetite. Another advantage of such an amino acid mixture is that it provides in conjunction with the added mineral salts, the iodine and the trace elements contained in KeIp for a balanced nitrogen balance.
Auch die weiteren verwendeten Aminosäuren üben vorteilhafte Wirkungen aus. So wirkt auch Glycin appetitzügelnd. Leucin stimuliert die Eiweissynthese (Muskelaufbau) und hält den Blutzuckerspiegel stabil. Arginin hat sich als wirkungsvoll gegen Arteriosklerose (Gefäßverkalkung) herausgestellt. Methionin ist an der Bildung von Noradrenalin und Camitin beteiligt, welches für den Transport der Fettsäuren durch die Mitochondrienmembran verantwortlich ist, wo der oxidative Abbau der Fettsäuren erfolgt. Prolin ist u. a. ein Ausgangsstoff für Polyamine, die für Zellwachstum und Zelldifferenzierung essentiell sind und anabole Wirkung entfalten.The other amino acids used also exert beneficial effects. Glycine also has an appetizing effect. Leucine stimulates protein synthesis (muscle growth) and keeps blood sugar levels stable. Arginine has been shown to be effective against arteriosclerosis (vascular calcification). Methionine is involved in the production of noradrenaline and camitine, which is responsible for the transport of fatty acids through the mitochondrial membrane, where the oxidative degradation of fatty acids occurs. Proline is u. a. a starting material for polyamines, which are essential for cell growth and cell differentiation and develop anabolic action.
Konkretes Ausführungsbeispiel:Specific embodiment:
Das Zusatznahrungsmittel besteht beispielsweise aus einer Aminosäuremischung bestehend aus L-Alanin 8,7 gThe additional foodstuff consists for example of an amino acid mixture consisting of L-alanine 8.7 g
L-Arginin 8,15 gL-arginine 8.15 g
L-Asparaginsäure 6 g L-Glutaminsäure 11,1 g L-Glycin 20,6 g L-Histidin 0,6 gL-aspartic acid 6 g L-glutamic acid 11.1 g L-Glycine 20.6 g L-histidine 0.6 g
L-Hydroxylysin 1 gL-hydroxylysine 1 g
L-Hydroxyprolin 11 ,4 g L-Isoleucin 1 ,6 gL-hydroxyproline 11, 4 g of L-isoleucine 1, 6 g
L-Leucin 3,3 gL-leucine 3.3 g
L-Lysin 3,9 gL-lysine 3.9 g
L-Methionin 0,6 gL-methionine 0.6 g
L-Phenylalanin 2,1 g L-Prolin 13,3 gL-phenylalanine 2.1 g L-proline 13.3 g
L-Serin 3,1 gL-serine 3.1 g
L-Threonin 1 ,8 gL-threonine 1, 8 g
L-Tyrosin 0,35 gL-tyrosine 0.35 g
L-Valin 2,4 g Weiterhin enthält das ZusatznahrungsmittelL-valine 2.4 g Further contains the additional food
Calciumphosphat 0,63 gCalcium phosphate 0.63 g
Magnesium 0,39 gMagnesium 0.39 g
Kalium 0,18 gPotassium 0.18 g
KeIp 0,05 g davon Jod 7,5 mg + Spuren Tomatenextrakt enthaltend Lycopin 0,18 g.KeIp 0.05 g of which iodine 7.5 mg + traces of tomato extract containing lycopene 0.18 g.
Das Nahrungsergänzungsmittel ist frei von Fett, frei von Kohlenhydraten, frei von Purin und frei von Cholesterin. Es wird im Rahmen einer Formula-Diät als Ersatz oder als Ergänzung von Mahlzeiten eingenommen. Die Dosierung liegt je nach Körpergewicht des Patienten zwischen 40 g pro Tag und 80 g pro Tag. Die Therapie sollte von qualifizierten Diätassistenten und/oder ärztlich begleitet sein.The dietary supplement is fat free, carbohydrate free, purine free and cholesterol free. It is taken as part of a formula diet as a substitute or as a supplement to meals. The dosage is ever according to body weight of the patient between 40 g per day and 80 g per day. The therapy should be accompanied by qualified dieticians and / or medically.
- Patentansprüche - - Claims -
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005043986.1 | 2005-09-14 | ||
DE102005043986A DE102005043986A1 (en) | 2005-09-14 | 2005-09-14 | Additional food |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007031291A2 true WO2007031291A2 (en) | 2007-03-22 |
WO2007031291A3 WO2007031291A3 (en) | 2007-05-10 |
Family
ID=37607245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/008911 WO2007031291A2 (en) | 2005-09-14 | 2006-09-13 | Foodstuff additive |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE102005043986A1 (en) |
WO (1) | WO2007031291A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL2009317C2 (en) * | 2012-08-13 | 2014-02-18 | Invent 4 You B V | Mutant tomatoes and use thereof for preventing weight gain and/or treating obesity-related conditions. |
US10183052B2 (en) | 2015-02-13 | 2019-01-22 | Green4Health B.V. | Mutant tomatoes and use thereof for preventing weight gain and/or treating obesity-related conditions |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2268871A (en) * | 1992-07-04 | 1994-01-26 | Bio Nutritional Health Service | Composition for use as a food or food supplement |
US5744161A (en) * | 1995-02-24 | 1998-04-28 | Sabinsa Corporation | Use of piperine as a bioavailability enhancer |
US6224871B1 (en) * | 1998-03-11 | 2001-05-01 | Reliv International, Inc. | Dietary supplement for nutritionally promoting healthy joint function |
GB2353471B (en) * | 1999-07-06 | 2004-08-18 | Daniel I Vigdorovich | Composition for treating obesity and related disorders and using therof |
WO2002012882A2 (en) * | 2000-08-08 | 2002-02-14 | Buchanan Baillie Hamilton Paul | Slimming system |
US7030092B1 (en) * | 2001-08-24 | 2006-04-18 | Small Giant L.L.C. | Ultra-high fiber supplement and method of reducing weight cardiovascular risks and ingested toxins. |
JP2003160505A (en) * | 2001-09-12 | 2003-06-03 | Lion Corp | Food and drink as well as external preparation with body fat reducing effect |
US20040001817A1 (en) * | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
US7445807B2 (en) * | 2002-10-15 | 2008-11-04 | Western Holdings, Llc | Agglomerated granular protein-rich nutritional supplement |
US20060115556A1 (en) * | 2004-12-01 | 2006-06-01 | Foulger Sidney W | Nutritional supplement drink containing xanthone extracts |
-
2005
- 2005-09-14 DE DE102005043986A patent/DE102005043986A1/en not_active Withdrawn
-
2006
- 2006-09-13 WO PCT/EP2006/008911 patent/WO2007031291A2/en active Application Filing
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL2009317C2 (en) * | 2012-08-13 | 2014-02-18 | Invent 4 You B V | Mutant tomatoes and use thereof for preventing weight gain and/or treating obesity-related conditions. |
WO2014027886A1 (en) * | 2012-08-13 | 2014-02-20 | Green4Health B.V. | Mutant tomatoes and use thereof for preventing weight gain and/or treating obesity-related conditions |
US10183052B2 (en) | 2015-02-13 | 2019-01-22 | Green4Health B.V. | Mutant tomatoes and use thereof for preventing weight gain and/or treating obesity-related conditions |
Also Published As
Publication number | Publication date |
---|---|
DE102005043986A1 (en) | 2007-04-05 |
WO2007031291A3 (en) | 2007-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5889040A (en) | Composition for increasing protein concentration in a mammal | |
US8168241B2 (en) | Performance-enhancing dietary supplement | |
US20090098230A1 (en) | Nutraceutical moringa composition | |
KR20020062927A (en) | Food supplement for increasing lean mass and strength | |
WO1994001006A2 (en) | Composition for use as a food or food supplement | |
GB2268871A (en) | Composition for use as a food or food supplement | |
CN108308493A (en) | A kind of anti-fatigue solid beverage and preparation method of astaxanthin-containing | |
Hewlings et al. | Sulfur in human health | |
RU2463811C1 (en) | Specialised product for sportspeople alimentation | |
CN102771690A (en) | Muscle building functional food | |
Rudolf et al. | Sport nutrition: the role of macronutrients and minerals in endurance exercises | |
WO2008100130A2 (en) | Composition containing kadok extract and collagen | |
US20060147600A1 (en) | 'Maca Blast' energy drink | |
RU2376888C2 (en) | Dietary supplement | |
WO2007031291A2 (en) | Foodstuff additive | |
RU2685883C1 (en) | Vitaminized drinking water | |
WO2020210540A2 (en) | Nutrient compositions and methods for administering a nutrient composition | |
Keith | Ascorbic acid | |
RU2492867C1 (en) | Biologically active additive | |
CN109170913A (en) | A kind of health composition of peptide containing bird's nest, soybean peptide and bone glue of yak former peptide | |
RU2105502C1 (en) | Biologically active preparation "methiovit" | |
Dorn et al. | A review of antler supplements: Benefits, trends, and potential | |
EP1214894B1 (en) | Food formulations with a high calcium content | |
EP1228706B1 (en) | Composition for enhancing the forming of connective tissue and for conditioning the body for high physical performance | |
US20180027853A1 (en) | Embryonic egg extract composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06792030 Country of ref document: EP Kind code of ref document: A2 |